close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Taysha Gene Therapies, Inc. - Common Stock (NQ:TSHA)

4.675 -0.045 (-0.95%)
Streaming Delayed Price Updated: 9:58 AM EDT, Oct 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Taysha Gene Therapies, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Taysha Gene Therapies Reports First Quarter 2021 Financial Results and Provides a Corporate Update
From Taysha Gene Therapies, Inc.
Via Business Wire
Earnings Scheduled For May 11, 2021
Companies Reporting Before The Bell • Oxford Lane Capital (NASDAQ:OXLC) is estimated to report earnings for its fourth quarter. • ReWalk Robotics (NASDAQ:RWLK) is... 
Via Benzinga
Taysha Gene Therapies' Rett Syndrome Candidate Shows Encouraging Action In Animal Studies, Human Trial To Start By 2021
Taysha Gene Therapies Inc (NASDAQ: TSHA) has announced the online publication of new preclinical data for TSHA-102 in Rett syndrome. The data will be included in... 
Via Benzinga
Taysha Gene Therapies Announces Publication of Preclinical Data for TSHA-102 in Rett Syndrome in Brain, a Highly Esteemed Neurological Science Peer-Reviewed Journal
From Taysha Gene Therapies, Inc.
Via Business Wire
Taysha Gene Therapies Announces Multiple Data Presentations and Workshop Presentations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy
From Taysha Gene Therapies, Inc.
Via Business Wire
Why Taysha Gene Therapies's Stock is Trading Higher Today
The Price And Volume Action In Taysha Gene Therapies's Stock Today Taysha Gene Therapies's (NASDAQ: 
Via Benzinga
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came... 
Via Benzinga
Taysha Gene Therapies to Release First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 11
From Taysha Gene Therapies, Inc.
Via Business Wire
Taysha Gene Therapies Announces New Data on Multiple Preclinical Programs and Upcoming R&D Day
From Taysha Gene Therapies, Inc.
Via Business Wire
What's Going On With MOSY Stock And TSHA Stock?
MoSys Inc. (NASDAQ: MOSY) shares are trading higher after the company announced it has expanded its patent portfolio through the purchase of five patents in the area of search and... 
Via Benzinga
Topics Intellectual Property
Mid-Afternoon Market Update: Dow Falls Over 100 Points; Canaan Shares Tumble After Q4 Results
Toward the end of trading Monday, the Dow traded down 0.32% to 33,691.74while the NASDAQ fell 0.52% to 13,828.15. The S&P also fell, dropping 0.20% to 4,120.43. The U.S. has... 
Via Benzinga
Topics Stocks
55 Biggest Movers From Yesterday
Gainers Celcuity Inc. (NASDAQ: CELC) jumped 29.4% to settle at $27.94. Celcuity shares climbed 51% on Friday after the company announced a worldwide licensing agreement with... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers 180 Life Sciences (NASDAQ:ATNF) shares increased by 27.31% to $12.4 during Monday's regular session. Trading volume for 180 Life Sciences's stock is 29.3... 
Via Benzinga
Mid-Day Market Update: Crude Oil Rises 2%; iRhythm Technologies Shares Plummet
Midway through trading Monday, the Dow traded down 0.22% to 33,725.47 while the NASDAQ fell 0.55% to 13,823.65. The S&P also fell, dropping 0.21% to 4,120.15. The U.S. has the... 
Via Benzinga
Topics Stocks
42 Stocks Moving In Monday's Mid-Day Session
Gainers Wilhelmina International, Inc. (NASDAQ: WHLM) shares jumped 44.8% to $8.05 after the company's 13D filing showed that Modell's Sporting Goods had reported a stake... 
Via Benzinga
Taysha Gene Therapies Stock Is Trading Higher After Buying Rights To New Gene Therapy Candidate For Neurodegenerative Disease
Taysha Gene Therapies Inc (NASDAQ: TSHA) has unveiled a deal for global rights to the AAV9 gene therapy program, now known as TSHA-120, to treat giant axonal... 
Via Benzinga
Taysha Gene Therapies Acquires Exclusive Worldwide Rights to Clinical-Stage AAV9 Gene Therapy Program, Now Known as TSHA-120, for the Treatment of Giant Axonal Neuropathy, a Rare and Severe Neurodegenerative Disease
From Taysha Gene Therapies, Inc.
Via Business Wire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today